Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann. Rheum.

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.

Interleukin Inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a CAGR of 12.6%. BURLINGAME, CA, UNITED STATES, December 18, ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

The team at the MRC Laboratory of Medical Science, Imperial College London and Duke-NUS Medical School in Singapore were investigating a protein called interleukin-11. Levels of it increase in the ...

Persistent shorter sleep duration across childhood may be a risk factor for subsequent psychosis in young adulthood.

A new diagnostic test using a dual-biomarker algorithm can inform osteoarthritis diagnosis with high accuracy.